Prognostic implications of preoperative diagnosis of clinically local and locally advanced prostatic cancer


Cite item

Full Text

Abstract

The data of preoperative diagnosis and morphological examination were compared for 144 patients with prostatic carcinoma T1-4N0-XM0 subjected to radical prostatectomy in 1997-2007. In assessment of prostatic capsule invasion, sensitivity of the rectal examination was 21.7%, specificity - 89.8%, diagnostic efficacy - 68.1%, PPV - 50.0%, NPV - 70.9%, AUC under ROC curve - 0.558 ± 0.053 (p = 0.348); sensitivity of transrectal ultrasonic investigation - 21.7%, specificity - 89.8%, diagnostic efficacy - 68.8%, PPV - 52.6%, NPV - 71.2%, AUC under ROC curve - 0.563 ± 0.053 (p = 0.211). Factors of a poor prognosis of prostatic capsule invasion were PSA > 10 ng/ml (p = 0.028) and Gleason score > 7 (p = 0.052). Combined use of these two parameters raises quality of preoperative assessment of category T [sensitivity - 80.0%, specificity - 55.1%, diagnostic efficacy - 56.3%, PPV - 80.4%, NPV - 44.9%, AUC under ROC curve - 0.624 ± 0.049 (p = 0.017)]. Sensitivity of clinical assessment of N category was 11.1% in 100% specificity, 94.4% diagnostic efficacy, 100% PPV, 94.4% NPV, 0.556 ± 0.107 (p = 0.577) AUC under ROC curve. A single significant prognostic factor of pN+ category was PSA > 10 ng/ml (p = 0.014). Sensitivity of histological examination of biopsy material in relation to true Gleasons parameter (<7 or >7) was 59.4%, specificity 89.3%, diagnostic efficacy 82.6%, PPV 61.3%, NPV 88.5%, AUC under ROC curve 0.743 ± 0.056 (p < 0.0001). Thus, combined use of a baseline PSA concentration with a borderline value > 10 ng/ml and biopsy Gleason score > 7 raises quality of preoperative evaluation of extraprostatic tumor extension and condition of regional lymph nodes.

References

  1. Van den Ouden D., Schrцder F. H. Management of locally advanced prostate cancer. 1. Staging, natural history, and results of radical surgery. Wld J. Urol. 2000; 18 (3): 194-203.
  2. Martinez de la Riva S. I., Lцpez-Tomasety J. B., Marrero Dominguez R., Santamaria Blanco P. Perineal radical prostatectomy as monotherapy: ten-year experience. Arch. Esp. Urol. 2004; 57 (4): 397-411.
  3. Partin A. W., Yoo J., Carter H. B. et al. The use of prostate specific antigen clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol. (Baltimore) 1993; 150 (1): 110-114.
  4. Dominique S., Ravery V. Preoperative imaging studies: Is there any necessity? EAU Update Ser. 2005; 3 (2): 72-76.
  5. Oesterling J. E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. (Baltimore) 1991; 145 (5): 907-923.
  6. Stamey T. A., Yang N., Hay A. R. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 1987; 317 (15): 909-916.
  7. Levitt J. M., Slawin K. M. Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression. Curr. Urol. Rep. 2007; 8 (4): 269-274.
  8. Roehrborn C. G., Boyle P., Gould A. L., Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53 (3): 581-589.
  9. Amiel J., Chevallier D., Peyrottes A. et al. Clinicopathologic and biological correlations (PSA-PAP) in pathology of the prostate. Apropos of 150 cases. J. Urol. (Paris) 1990; 96 (4): 199-201.
  10. Guimaraes M. S., Quintal M. M., Meirelles L. R. et al. Gleason score as predictor of clinicopathologic findings and biochemical (PSA) progression following radical prostatectomy. Int. Braz. J. Urol. 2008; 34 (1): 23-29.
  11. Chun F. K.-N., Steuber T., Erbesdobler A. et al. Development and internal validation of a nomogramm predicting of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur. Urol. 2006; 49: 820-826.
  12. Chun F. K.-N., Karakiewicz P. I., Briganti A. et al. Prostate cancer nomograms: An update. Eur. Urol. 2006; 50: 914-916.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies